CRS 2025 Annual Meeting & Exposition
The CRS 2025 Annual Meeting & Exposition highlights the exciting advancements shaping the future of controlled release science. Join us for an inspiring week of insightful presentations, engaging discussions, and networking opportunities with leading innovators from around the world that are influencing the future of drug delivery.
Date: July 14-18, 2025
Location: Philadelphia, PA
JOIN US!
Join us at CRS 2025 to learn how Catalent can support your drug development journey with Zydis® ODT and advance patient-centric therapies through enhanced ease of administration and improved adherence. Schedule a meeting today!
SPEAKING ENGAGEMENTS
Enhancing Patient Care Through Advancements in Orally Disintegrating Tablets
Charli Smardon, Senior Formulation Scientist, Catalent
Thursday, July 17 at 2:00 PM
Orally disintegrating tablets (ODTs) continue to redefine patient-centric drug delivery by combining convenience, efficacy, and compliance, especially for populations with swallowing difficulties such as pediatric, geriatric, and oncology patients. Among ODT technologies, Zydis®, Catalent’s proprietary lyophilized platform, offers ultra-rapid disintegration without the need for water and enables oromucosal dispersion for faster onset of action and potential for pre-gastric absorption. Zydis® has successfully supported the commercialization of multiple small molecule therapies and is now being applied to emerging modalities, including peptides and novel molecular entities.
Novel coating strategies under evaluation may also support the development of extended-release Zydis® formulations, expanding its potential beyond immediate-release applications. This work includes ongoing evaluations using model compounds such as ibuprofen to illustrate extended-release potential and regulatory feasibility. Attendees will gain insight into how Zydis® enables differentiated products, lifecycle extension, and improved patient access across a growing spectrum of therapeutic areas, including high-impact applications in oncology, where ease of administration is critical for patients undergoing chemotherapy.
ABOUT CATALENT
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. www.catalent.com.
